Menu
CEO George Thomas speaks to Proactive after launching a new platform described as the “Uber for mobile phlebotomy.”
With an increasing need for affordable, convenient, community based health testing, Goodbody is well-poised to support customers to Know More and Live Better.
CEO George Thomas talks to Proactive about the sale of the CBD extraction plant and what this means for the Goodbody Health business in 2023 and beyond.
With an increasing need for affordable, convenient, community based health testing, Goodbody is well-poised to support customers to Know More and Live Better.
“With the pressures placed on the NHS, who are now operating a ’late diagnosis service’ for cancer, there has never been a better time to start looking after our health starting with general self-care before symptoms appear through our blood testing services.
Tests such as our Goodbody Hereditary Cancer Genetic Tests , which are DNA tests which determine whether you have a genetic mutation which makes you prone to developing cancer, are an excellent way you can identify your risks and monitor your health while considering lifestyle changes to reduce those risks.” Marc Howells, CEO Goodbody Health.
Marc Howells, Chief Executive Officer of the Goodbody Health Group discusses progress so far in 2022, as well as addressing stake holder questions.
Geremy Thomas, executive chairman, explains why Goodbody Health is switching its listing from Canada to London.
It’s hard to justify the cost of being in Vancouver, he says, and with cash king at the moment the money can be used to invest in its clinics in the UK, which will be focused on blood tests and wellness now that Covid-19 is easing.
All around, the target is to cut unnecessary expenses, he adds.
Marc shares his views on a under resourced and over burdened NHS, a change in how people manage their health, how Goodbody Health is meeting the massive growing demand for its services and can the company continue to grow at such speed.
George explains the submission process, what the FSA Public list announcement means, what it means for Goodbody and the implication this has for consumers.
George shares his thoughts on whether people are taking heart health seriously enough, if they need to be more proactive in managing their heart health, what a blood MOT consist of and the experience Goodbody Health has built-up in blood testing.
Founder Geremy Thomas, talking with the Canadian Securities Exchange.
Goodbody Health Inc. Scientific Advisory Committee Member Dr Jamie Brosch joins DirectorsTalk Interviews to share his views on the company.
Many of our shareholders who hold Goodbody Health shares through Hargreaves Lansdown have shown frustration that they cannot trade electronically.
We have tried on your behalf to rectify this situation with Hargreaves Lansdown. Although we know we are not the only company for whom their electronic platform is unavailable we still feel this needs to be rectified, as they are one of the largest platforms. Our shares can be traded electronically on a number of platforms as detailed on our website We have been asked repeatedly to resolve the situation with Hargreaves Lansdowne and it has even been suggested on many occasions that our share price may be affected by this issue which is why we are keen to elicit your influence to resolve this matter.
What may help is if our shareholders who trade through Hargreaves Lansdowne raise this as a concern with them. If you would like this rectified, please express your views on the matter to:
https://www.hl.co.uk/contact-us/email-us
Hargreaves Lansdown Investment Helpdesk: 0117 900 9000
Monday – Friday: 8am – 5pm
Saturday: 9.30am – 12.30pm
According to Diabetes UK, at the moment 13.6 million people are at increased risk of type 2 diabetes in the UK. If you don’t have it yet, and with the right support, up to 50% of cases of type 2 diabetes can be prevented or delayed.
The Sunday Times reported on the 6 February 2022 that a new blood testing technique due to be introduced by the NHS will determine how likely a patient is to have cancer.
The Board of The National Institute for Health and Care Excellence (NICE), provided an update on 20th January 2022 on how it plans to evaluate promising new health technologies and making patient access fairer.
Ian Strachan, Scientific Advisory Committee Member talks about Goodbody Health.
Sativa Wellness Group inc. have changed its name to Goodbody Health Inc, adopting the name of its main brand. The new ticker symbol on the AQSE Growth Market and Canadian Securities Exchange will be GBDY. This follows the firm’s successes of 2021 in delivering health…
Marc Howells, Chief Executive Officer talks through the investor presentation.
Sativa Wellness Group Inc have been recently featured on the news.financial website in an interesting article written by Stefan Feulner.
A link to this article can be found below.
Sativa Wellness Group inc. (LON:SWEL) Executive Chairman Geremy Thomas joins DirectorsTalk Interviews to discuss its first quarterly profit in Q2 2021. Geremy talks us through the results highlights and explains the companies plans for the second half.
Sativa Wellness Group Inc’s (LON:SWEL) (CSE: SWEI) Geremy Thomas talks to Proactive London’s Katie Pilbeam about their Q1 2021 financial statements.
Sativa Wellness Group Inc’s (LON:SWEL) Geremy Thomas talks to Proactive London’s Katie Pilbeam about subsidiary PhytoVista Laboratories , which has been was granted ISO/IEC 17025:2017 accreditation from the UK for the testing of cannabinoids.
Sativa Wellness Group Inc. (LON:SWEL) Executive Chairman Geremy Thomas joins DirectorsTalk to discuss now being listed on the UK government website to offer 2 and 8 day quarantine tests. Geremy explains where they are with the clinic roll-out and how this will impact revenues.
SATIVA Wellness’ pivot to Covid-19 testing work has exceeded expectations with plans afoot to open up a dozen new locations delivering blood tests, vaccines and vaccine boosters.
Previously know as The Sativa Group the name change to Sativa Wellness in October last year reflected its efforts in the fight against the pandemic.
read more…
Sativa Wellness Group Inc. (AQSE:SWEL / CNSX:SWEL) Executive Chairman Geremy Thomas joins DirectorsTalk Interviews to discuss reaching its £1m milestone for COVID testing. Geremy talks us through the milestone, the addition of further testing clinics including two mobile units, the significance of having 30 clinics to the company and how long Geremy thinks the PCR testing revenue stream will last.
Sativa Wellness Group Inc’s (LON:SWEL) Geremy Thomas talks to Proactive London’s Katie Pilbeam about its coronavirus (COVID-19) testing business which has now achieved over £1.1mln worth of bookings in less than four months since opening its first clinic in Bath, UK.
The company now has 17 operational clinics throughout the UK testing for COVID-19, in line with its target to have 30 clinics by the end of April.
Sativa Wellness Group Inc. (AQSE:SWEL / CNSX:SWEL) Executive Chairman Geremy Thomas joins DirectorsTalk to discuss its operations meeting the requirements of Good Manufacturing Practice and Good Hygiene Practice standards for food manufacturing. Geremy explains what this means for the company, the impact this has on the Novel Foods accreditation and now with David Beckham as a competitor, how he feels about that.
Sativa Wellness Group Inc’s (LON:SWEL) Geremy Thomas talks to Proactive London about being back at the helm with his focus on generating cash and profit as well as reducing costs.
He says, ‘since I’ve been in place we’ve seen a doubling of our share price and I think that will continue to rise‘.
Sativa Wellness Group Inc. (CNSX:SWEL) Executive Chairman Geremy Thomas joins DirectorsTalk Interviews to discuss its novel food application to the FSA. Geremy explains why he has re-joined the board, the significance of the application announcement and the recent success of new listings in this CBD sector.
